Utility of plasmalogen based therapeutics for neurodegenerative and psychiatric disorders

June 15, 2016

Dr. Dayan Goodenowe describes the utility of plasmalogen based therapeutics for neurodegenerative and psychiatric disorders at the annual Canadian College of Neuropsychopharmacology meeting

On June 15, 2016, Dr. Dayan Goodenowe, founder of Prodrome Sciences Inc., presented research results supporting the use of plasmalogen-based therapeutics for the treatment and prevention of Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis.

Plasmalogens are a type of lipid (fat) that your body uses to keep cellular membranes in good working order. They are especially important for neurons in your brain. When your membranes do not have enough of these lipid molecules, they become rigid and stop functioning properly.

Dr. Goodenowe presented evidence that reduced levels of these molecules in your blood is linked to an increased risk of Alzheimer’s disease and Parkinson’s disease. Dr. Goodenowe also presented pre-clinical evidence that the use of plasmalogen-elevating therapeutics can prevent dopaminergic denervation (the hallmark pathology of Parkinson’s disease) and demyelination (the hallmark pathology of multiple sclerosis), and reduce the formation of beta-amyloid (the hallmark pathology of Alzheimer’s disease).

Dr. Goodenowe’s hypothesis is that the inability to make sufficient amounts of plasmalogen molecules to maintain neuronal membrane integrity is the root of the prodrome for several neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis. Dr. Goodenowe is the inventor of several patents relating to the role of plasmalogens in neurodegenerative disease. 

Contact us for more information.

Keep in touch

©2019 Prodrome Sciences Inc.

Search